Asensus Surgical, Inc. is a medical technology company specializing in digital laparoscopic surgical robotics. The company develops systems and software designed to enhance the precision, reproducibility and control of minimally invasive surgical procedures. Its flagship offering, the Senhance® Surgical System, integrates advanced instrument tracking, proprietary haptic feedback and ergonomic instrumentation to allow surgeons greater dexterity and tactile perception during keyhole operations.
The Senhance system supports a range of general, gynecologic, urologic and bariatric procedures by combining conventional laparoscopic tools with a digital surgery platform. Through real-time data capture and analytics, the system provides performance metrics and vision-guided instrument control, including eye-tracking camera movement. Asensus also offers support services, training programs and modular software upgrades to help hospitals and surgical teams maximize device utilization and efficiency.
Originally founded as TransEnterix in 1999 and headquartered in Durham, North Carolina, the company achieved CE mark approval for its robotic platform in Europe and subsequently secured FDA clearance in the United States. In late 2021, it rebranded as Asensus Surgical to reflect its strategic focus on augmenting human performance with data-driven technologies. The company has since expanded its commercial footprint across North America, Europe, the Middle East and select Asia-Pacific markets.
Led by an executive team with deep expertise in medical devices, robotics and digital health, Asensus Surgical aims to transform minimally invasive surgery by democratizing robotic capabilities and harnessing the power of data. Its ongoing research and development efforts are focused on expanding the clinical applications of its platform and integrating advanced software tools to support evidence-based surgical decision-making.
AI Generated. May Contain Errors.
